Immediate contingency plans should be put in place to safeguard the UK’s science and innovation sector in case Britain votes to leave the EU, a government report has said.
It comes at the end of a six-month inquiry by the UK government’s Science and Technology committee into the impact of EU legislation and regulation in the life sciences.
The committee was told the UK could potentially lose more than £1 billion ($1.43 billion) in vital EU research funding in the event of Brexit.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze